January 26, 2012
By:From staff reports
Indian drug giant Ranbaxy has accepted a consent decree filed by the U.S. Department of Justice on behalf of FDA. The decree, which must still be accepted by the U.S. District Court for the District of Maryland, requires Ranbaxy to fix long-standing manufacturing problems at plants in India as well as a plant in the United States.
 |
July 1, 2011
By:Michele B. Kaufman, PharmD, RPh
Some of the most prescribed blockbuster medications will lose market exclusivity in the next couple of years, according to a recent presentation.
|
July 1, 2011
By:Fred Gebhart
Low-cost generic drug programs pioneered by Wal-Mart and other big-box retailers are a mixed blessing for patients with diabetes.
|
July 1, 2011
The 5-alpha-reductase inhibitor dutasteride is associated with markedly lower BPH-related complication rates than the alpha-blocker tamsulosin, according to analysis of 2 large trials.
|
July 1, 2011
The selective beta3-adrenoceptor agonist mirabegron effectively improves symptoms of overactive bladder and is very safe and well tolderated, according to results of a phase 3 study.
|
May 14, 2009
By:Formulary staff
2008 Top 100 branded drugs by total prescriptions and total retail dollars
|
April 1, 2009
By:Formulary staff
In a multinational prospective study published in the BMJ, investigators demonstrated that parenteral medication errors are common occurrences in intensive care units (ICUs), but the number of errors can be reduced through the use of error-reporting and electronic prescribing systems.
|
December 15, 2008
Evidence supports the clinical equivalence of generic and brand-name cardiovascular drugs, according to a meta-analysis published in the Journal of the American Medical Association. Despite this evidence, more than half of the editorials discussing the issue of generic interchangeability that were assessed in this analysis do not support generic substitution for brand-name cardiovascular drugs.
|
December 1, 2008
By:Janice Ma, PharmD, Alan Gervais, BSP, Julie Lanouette, RN
In 2003, the Canadian Forces (CF) drug benefit plan used preferential listing to control costs associated with proton pump inhibitors (PPIs); however, significant expenditures for nonbenefit PPIs continued. A database review was thus conducted to explain this anomalous usage pattern. This study provides further information regarding the effectiveness of preferred listing as a cost-saving measure, noting that adherence to such policies may be less than projected.
|
| 
Formulary archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians.